For treatment-naïve adults with HIV-1. See Full Indication.

DHHS Recommendation for Dovato

DOVATO is

NOW A DHHS-RECOMMENDED
INITIAL REGIMEN

for Most People With HIV-11

PANEL NOW RECOMMENDS

DTG/3TC (AI)*

Except for individuals:
  • With HBV co-infection
  • Who will start ART before results of HIV genotypic resistance testing for RT or HBV testing are available
  • With HIV RNA >500,000 copies/mL
  •  

 

  • Rating of Recommendations=Strong
  • Rating of Evidence=Data from randomized controlled trials

 

Not an actual patient.

 

*Rating of Recommendations: A=strong; B=moderate; C=optional. Rating of Evidence: I=data from randomized controlled trials; II=data from well-designed nonrandomized trials, observational cohort studies with long-term clinical outcomes, relative bioavailability/bioequivalence studies, or regimen comparisons from randomized switch studies; III=expert opinion.

 

3TC=lamivudine; ART=antiretroviral therapy; DHHS=Department of Health and Human Services; DTG=dolutegravir; HBV=hepatitis B virus; RT=reverse transcriptase.

Reference: 1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. US Department of Health and Human Services. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Updated December 18, 2019. Accessed December 19, 2019.

Please see full Prescribing Information, including Boxed Warning, for DOVATO.

DLLWCNT190040